
01/24/2025
Great article published by Michael T McDermott on “Pseudo-endocrine disorders” (proposed endocrine conditions that have never been scientifically proven to exist) that, due to widespread misinformation available on the internet and other media, are unfortunately diagnosed and treated with equally unproven and sometimes dangerous treatments.
is a nonexistent condition that supposedly results from adrenal exhaustion and atrophy due to chronic stress and has been promoted as a potential explanation for a variety of symptoms. Testing consists of non validated online surveys and salivary cortisol profiles while treatment is not evidence-based at best and can be dangerous.
's syndrome and syndrome are also nonexistent conditions that supposedly result from impaired T4 to T3 conversion and competition of excess reverse T3 with T3 for T3 receptors. Testing involves measurement of axillary temperature and treatment consists of T3 therapy, often at very high and dangerous doses.
Hypogonadism (“low T”) is frequently diagnosed in “men's health” clinics and other venues without actual hormone testing or further evaluation and is often treated with supraphysiologic testosterone therapy that suppresses endogenous gonadal testosterone and s***m production, leads to a lifelong need for testosterone therapy, and may have numerous other harmful effects.
Low-dose naltrexone (LDN) therapy has been proposed as a treatment for multiple disorders including autoimmune conditions and other disorders resulting from aberrant immune mechanisms, but there is no valid evidence that LDN has any benefits.
Management of patients with pseudo-endocrine disorders must involve careful listening, patient education, healthy lifestyle measures, and honesty, encouragement, and compassion.
I would add that it is critical to empower patients to work with their real medical team, from primary care to specialists, for getting to the actual root and treatment of their actual ailments.
Journal of the Endocrine Society
https://academic.oup.com/jes/article/9/1/bvae226/7926880